Dialysis Player Fresenius Medical's Q4 Sales Hold Steady: Details
Portfolio Pulse from Vandana Singh
Fresenius Medical Care AG (NYSE:FMS) reported Q4 2023 revenue of €4.9 billion, nearly matching consensus estimates and showing flat year-over-year growth. Adjusted EPS increased by 4% to €0.88, surpassing consensus. The company treated 332,548 patients in 3,925 clinics worldwide and proposed a 6% dividend increase. For 2024, it expects low- to mid-single-digit revenue growth and mid- to high-teens operating income growth. Fresenius forecasts 0.5%-2% patient volume growth, slightly lower than DaVita Inc's (NYSE:DVA) 1%-2% expectations. FMS shares dropped 2.96% to $20.49.
February 20, 2024 | 6:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DaVita Inc's patient volume growth expectations for 2024 are slightly higher than Fresenius Medical Care's, potentially indicating stronger performance.
DaVita Inc's slightly higher patient volume growth expectations compared to Fresenius Medical Care could be viewed positively by investors, suggesting potential for stronger performance. However, the direct impact on DVA's stock price may be moderated by broader market conditions and company-specific factors.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Fresenius Medical Care reported stable Q4 2023 revenue and a slight increase in adjusted EPS, with a positive outlook for 2024. However, shares fell by 2.96%.
The slight drop in FMS shares despite meeting revenue expectations and surpassing EPS estimates suggests market concerns may be about the modest patient volume growth forecast or broader market conditions. The positive outlook for 2024 indicates underlying strength, but the immediate stock price reaction was negative.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100